


QUANTA Lite®

Anti-PS/PT IgG & IgM



Clarity

Identifies Antiphospholipid Syndrome (APS) patients that other tests may miss*



N=121

Sensitivity contributions for PS/PT and β_2 GP1 in detection of APS.²

The QUANTA Lite anti-phosphatidylserine/prothrombin (PS/PT) IgG and IgM assays accurately identify more APS patients than traditional serology methods without the need to interrupt anti-coagulation therapy.

- Superior clinical performance is delivered by targeting the entire PS/PT complex rather than just PS or PT alone¹
- When combined with β_2 GP1, the QUANTA Lite anti-PS/PT assays detect a wider range of APS patients

Clinical performance characteristics³

Sensitive

- The combination of PS/PT IgG and IgM assays successfully detected:
 - 100% (24 of 24) of suspected APS patients positive for lupus anticoagulant
 - 67.6% (48 of 71) of confirmed APS patients

Specific

- The combination of PS/PT IgG and IgM assays accurately identified:
 - 97.2% (240 of 247) of normal controls
 - 98.1% (51 of 52) of diseased controls including 23% known Syphilis patients

Cohort	# Samples	β ₂ GP1 IgG	β ₂ GP1 IgM	PS/PT IgG	PS/PT IgM	PS/PT IgG and/or IgM
Antiphospholipid Syndrome (APS)	71	31 (43.7%)	21 (29.6%)	33 (46.5%)	34 (47.9%)	48 (67.6%)
Lupus Anticoagulant Positive (LAC)	24	20 (83.3%)	16 (66.7%)	21 (87.5%)	19 (79.2%)	24 (100%)
Normals	247	N/A	N/A	3 (1.2%)	4 (1.6%)	7 (2.8%)
Disease Controls	52	N/A	N/A	0	1 (.019%)	1 (.019%)

A full range of tests for Antiphospholipid Syndrome

QUANTA Lite anti-PS/PT assays deliver optimal results when used in combination with other QUANTA Lite APS products.

Product Ordering Information	IgA	IgG	IgM	Screen (IgA/IgG/IgM)
QUANTA Lite Phosphatidylserine	704635	704625	704630	
QUANTA Lite ACA III	708635	708625	708630	708620
QUANTA Lite B ₂ GPI	708675	708665	708670	708660
QUANTA Lite anti-PS/PT (anti-phosphatidylserine and prothrombin)		708835	708845	

For more information, visit www.inovadx.com.

* For use in conjunction with other laboratory and clinical findings as an aid in the diagnosis of certain autoimmune thrombotic disorders, such as antiphospholipid syndrome (APS) and those secondary to systemic lupus erythematosus or other lupus-like diseases.

References

1. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). *J Thromb Haemost.* 2006;4(2):295-306.
2. Data on file.
3. QUANTA Lite aPS/PT IgG/IgM ELISA directional inserts.



Redefining Autoimmunity.

San Diego, CA 92131 USA
 PH: +1-858-586-9900 US Toll Free: 1-800-545-9495 FAX: +1-858-586-9911

QUANTA Lite is a registered trademark of INOVA Diagnostics, Inc. © 2010 INOVA Diagnostics, Inc. All rights reserved.

690117 November 2010 Rev. 4